Home > Boards > US OTC > Delisted > Intellicell Biosciences, Inc. (fka SVFC)

Publication in The American Journal of Medicine showing

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cazual Member Profile
Followed By 177
Posts 12,831
Boards Moderated 0
Alias Born 10/09/12
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
cazual   Sunday, 05/11/14 10:02:31 AM
Re: canitocano73 post# 66057
Post # of 91005 
Publication in The American Journal of Medicine showing regenerative results of cardiac function with SVFC's patented technology.

Zain Khalpey, MD, PhD, Rajesh Janardhanan, MD, John Konhilas, PhD, Courtney Hemphill, BS. First in Man: Adipose-derived Stromal Vascular Fraction Cells May Promote Restorative Cardiac Function, Amer J Med. 2014; 127,5: e11-e12

Article Outline

1. Case Summary
2. Discussion
3. Conclusions

To the Editor:
Despite advances in clinical intervention, heart disease remains a causation of mortality in the world. Research demonstrates that the adipose-derived stromal vascular fraction of cells contains multi-potent cells that exhibit mesodermal and ectodermal capacity and contain CD44+, CD90+, CD73+, CD105+, CD34+, and CD31+ cells, which act in tissue regeneration and vascular stabilization.1 We discuss a patient who underwent such cell administration as rescue therapy for failing cardiac function, despite conventional

Case Summary

The patient is a 73-year-old white man with a history of hyperlipidemia who presented with recurrent angina pectoris, for which he had undergone multiple angioplasties and 9 coronary stents (right posterior descending and distal right coronary beyond a saphenous vein graft to right coronary artery). He had further percutaneous coronary intervention to the distal right coronary artery and proximal posterior descending branch. His prior coronary bypass artery graft of 3 vessels had been redone. Robotic-assisted transmyocardial revascularization for angina was performed in the patient 2 months before cell delivery. He had significant left ventricular systolic dysfunction (ejection fraction, 20%) with a thinned, akinetic inferolateral segment. To evaluate left ventricular function, transesophageal echocardiography was performed in the patient.

As a last resort intervention for the patient's dysfunctional heart, 100 million adipose-derived stromal vascular fraction cells were delivered via localized intramyocardial injection (left apex), and 200 million adipose-derived stromal vascular fraction cells were delivered systemically via intravenous injection. The intracoronary delivery of freshly isolated autologous cells consisted of a complex cell composition. This uncultured population taken from lipoaspirate, which had an approximately 86% viability, consisted of CD34+ cells.

Within 7 days of the procedure, transesophageal echocardiography was performed to evaluate recovery of the patient's left ventricular function. His ejection fraction improved to 35% with recovery in the contractility of the previously akinetic inferolateral segment. This confirmed the effectiveness of cell delivery in improving regional and global left ventricular systolic function.


Spontaneous recovery of the damaged myocardium occurred. The effective delivery of the stromal vascular fraction cell population, which contained stem cells, may have improved regional and global left ventricular systolic function, aiding recovery. Adipose-derived stromal vascular fraction cells may have cardiomyogenic potential. Cellular composition of cells administered included endothelial progenitor cells, vascular smooth muscle cells, mesenchymal stem cells, fibroblasts, growth factors, and pericytes. This complex population has shown efficacy in repairing damaged tissue to partial restoration of functional normalcy.2

Angiogenesis may contribute to restoration of cardiac function through preservation of remaining viable and hibernating cardiomyocytes. This salvaging effect might be maintenance of border zone cells through stem cell–mediated anti-apoptotic and neoangiogenic effects, which are causative of stem cell–produced paracrine factors.1 This cell population has a high expression in DKK-1 and ID proteins, which are associated with regulation of stem cell proliferation and differentiation.2


We postulate that the intramyocardial administration of multi-potent adipose-derived stromal vascular fraction cells and their diverse composition guided engraftment in the damaged area, facilitated the cardiomyocyte regenerative properties, and helped improve cardiac function.
Because subcutaneous adipose tissue is readily available in most patients, adipose-derived stromal vascular fraction cells present a feasible clinical intervention for cardiac dysfunction. The population complexity, which includes stromal vascular fraction and growth factors, likely promotes repair by recruiting cardiomyocytes. The autologous nature and multi-potency of these cells may contribute to them being ideal for cardiac function restoration.


The authors thank Dr Steven Victor and Stephanie Squicciarini of IntelliCell Biosciences Inc (New York, NY) for supplying stromal vascular fraction, Dr Craig Hurst for providing lipoaspirate, and the patient and family.


Alt, E., Pinkernell, K., Scharalau, M. et al. Effect of freshly isolated autologous tissue resident stromal cells on cardiac function and perfusion following acute myocardial infarction. Int J Cardiol. 2009; 144: 26–35
View in Article | Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)
Lin, K., Matsubara, Masuda, Y. et al. Characterization of adipose tissue-derived cells isolated with Celution™ system. Cytotherapy. 2008; 10: 417–426
View in Article | Abstract | Full Text | Full Text PDF | PubMed | Scopus (64)
Funding: Provided by the University of Arizona College of Medicine, Department of Surgery, Division of Cardiothoracic Surgery.

Conflict of Interest: None.

Authorship: All authors had access to the data and played a role in writing this manuscript.






Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences